Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 6/20 | 0.50 |
| ▸ | BCR | P11274 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | GALR2 | O43603 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21434147 | 0.83 | NPC1 (0.53) | NPC1TSHRRECQLRAB9ASMN1; SMN2 | |
| SCHEMBL21434145 | 0.82 | KMO (0.57) | NPC1TSHRRECQLRAB9ASMN1; SMN2 | |
| SCHEMBL21434116 | 0.82 | NPC1 (0.52) | NPC1TSHRRECQLRAB9ASMN1; SMN2 | |
| SCHEMBL21434142 | 0.81 | TSHR (0.51) | NPC1TSHRRECQLRAB9ASMN1; SMN2 | |
| SCHEMBL21433972 | 0.81 | ITGB2 (0.54) | NPC1RAB9ASMN1; SMN2ABL1BCR | |
| SCHEMBL21434101 | 0.80 | KMT2A (0.61) | TSHRSMN1; SMN2MAPTTP53HRH4 | |
| SCHEMBL21434097 | 0.80 | ITGB2 (0.56) | ABL1BCRDPP4LRRK2PIK3CA | |
| SCHEMBL21434184 | 0.78 | GALR2 (0.53) | TSHRSMN1; SMN2MAPTTP53HRH4 | |
| SCHEMBL4358367 | 0.77 | KDM4E (0.50) | NPC1RAB9AMAPTTP53KDM4E | |
| SCHEMBL21434158 | 0.77 | TP53 (0.48) | TSHRMAPTTP53HRH4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | NPC1 3441/4885TSHR 1099/4885RECQL 2899/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | NPC1 3441/4885TSHR 1099/4885RECQL 2899/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | NPC1 3519/4885TSHR 1134/4885RECQL 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.